PepGen Ltd (NASDAQ:PEPG) — Market Cap & Net Worth
Market Cap & Net Worth: PepGen Ltd (PEPG)
PepGen Ltd (NASDAQ:PEPG) has a market capitalization of $121.74 Million ($121.74 Million) as of June 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #18549 globally and #4243 in its home market, demonstrating a 29.71% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying PepGen Ltd's stock price $1.79 by its total outstanding shares 69169215 (69.17 Million). Review debt load of PepGen Ltd to assess the company's total debt and financial obligations.
PepGen Ltd Market Cap History: 2022 to 2026
PepGen Ltd's market capitalization history from 2022 to 2026. Data shows change from $924.79 Million to $123.81 Million (-38.07% CAGR).
Index Memberships
PepGen Ltd is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.42 Trillion | 0.01% | #521 of 976 |
|
NASDAQ Composite
IXIC
|
$41.03 Trillion | 0.00% | #1804 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.69 Trillion | 0.01% | #237 of 263 |
Weight: PepGen Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
PepGen Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how PepGen Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of PEPG by Market Capitalization
Companies near PepGen Ltd in the global market cap rankings as of June 19, 2026.
Key companies related to PepGen Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #445 globally with a market cap of $62.84 Billion USD.
- UCB SA (BR:UCB): Ranked #547 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $451.63 |
| #445 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.84 Billion | $609.94 |
| #547 | UCB SA | BR:UCB | $49.68 Billion | €249.20 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €762.80 |
PepGen Ltd Historical Marketcap From 2022 to 2026
Between 2022 and today, PepGen Ltd's market cap moved from $924.79 Million to $ 123.81 Million, with a yearly change of -38.07%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $123.81 Million | -72.50% |
| 2025 | $450.29 Million | +71.77% |
| 2024 | $262.15 Million | -44.26% |
| 2023 | $470.35 Million | -49.14% |
| 2022 | $924.79 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 19th, 2026 the market cap of PepGen Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $121.74 Million USD |
| MoneyControl | $121.74 Million USD |
| MarketWatch | $121.74 Million USD |
| marketcap.company | $121.74 Million USD |
| Reuters | $121.74 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About PepGen Ltd
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatm… Read more